Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027